Association of PD-L1 Expression with Immunohistochemical Molecular Profile in Endometrial Carcinomas

Abstract Objective: PD-L1 expression is a potential biomarker for predicting immunotherapy response, but its role in endometrial carcinoma (EC) is unclear. This study evaluated PD-L1 expression in tumor cells (TC), immune cells (IC), and by the combined positive score (CPS), and examined associations with mismatch repair (MMR) status, p53 immunophenotype, and clinicopathological features. Methods: A total of 299 EC cases were retrospectively analyzed. PD-L1 was assessed by immunohistochemistry using TC, IC, and CPS scoring. MMR proteins (MLH1, PMS2, MSH2, MSH6) and p53 expression were also evaluated, and correlations with histological subtype, grade, and clinical parameters were examined. Results: PD-L1 positivity was observed in 33.9% of IC, 16.2% of TC, and 35.7% of CPS cases. IC and CPS expression were significantly associated with low-grade tumors (p < 0.001). MMR-deficient tumors demonstrated higher PD-L1 expression across all scoring methods (p < 0.001 for IC/CPS; p = 0.020 for TC). In addition, p53 mutation correlated with MMR stability (p = 0.014) and with PD-L1 TC positivity (p = 0.044). Conclusion: PD-L1 expression in TC correlated with p53 status and was linked to MMR deficiency. Combined evaluation of PD-L1, MMR, and p53 may aid stratification and guide immunotherapy in EC.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-10457939/v1
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Association of PD-L1 Expression with Immunohistochemical Molecular Profile in Endometrial Carcinomas

Hande Karabaş, Erdem Çomut, Nursinem Alkan Vurğun, Yeliz Arman Karakaya et al.
1 links
Research Square
Endometrial and Cervical Cancer Treatments
preprint

Association of PD-L1 Expression with Immunohistochemical Molecular Profile in Endometrial Carcinomas

Hande Karabaş, Erdem Çomut, Nursinem Alkan Vurğun, Yeliz Arman Karakaya, Derya KILIÇ GÜLER
preprint en

Abstract

Abstract Objective: PD-L1 expression is a potential biomarker for predicting immunotherapy response, but its role in endometrial carcinoma (EC) is unclear. This study evaluated PD-L1 expression in tumor cells (TC), immune cells (IC), and by the combined positive score (CPS), and examined associations with mismatch repair (MMR) status, p53 immunophenotype, and clinicopathological features. Methods: A total of 299 EC cases were retrospectively analyzed. PD-L1 was assessed by immunohistochemistry using TC, IC, and CPS scoring. MMR proteins (MLH1, PMS2, MSH2, MSH6) and p53 expression were also evaluated, and correlations with histological subtype, grade, and clinical parameters were examined. Results: PD-L1 positivity was observed in 33.9% of IC, 16.2% of TC, and 35.7% of CPS cases. IC and CPS expression were significantly associated with low-grade tumors (p < 0.001). MMR-deficient tumors demonstrated higher PD-L1 expression across all scoring methods (p < 0.001 for IC/CPS; p = 0.020 for TC). In addition, p53 mutation correlated with MMR stability (p = 0.014) and with PD-L1 TC positivity (p = 0.044). Conclusion: PD-L1 expression in TC correlated with p53 status and was linked to MMR deficiency. Combined evaluation of PD-L1, MMR, and p53 may aid stratification and guide immunotherapy in EC.

Research Square
Pamukkale University (TR)
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon